Clinical Updates & Treatment Advances in Metastatic Cervical Cancer from SGO
SGO 2022 on Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: A Cost-Effectiveness Analysis
By
SGO 2022 Conference Coverage on VuMedi
FEATURING
David Barrington
By
SGO 2022 Conference Coverage on VuMedi
FEATURING
David Barrington
Login to view comments.
Click here to Login
Clinical Updates & Treatment Advances in Metastatic Cervical Cancer from SGO